Julián Alejandro Rivillas/LinkedIn
Oct 24, 2025, 12:08
Julián Alejandro Rivillas Compares Tenecteplase to Low-dose Alteplase: TRACE-5 Interim Phase II Results
Julián Alejandro Rivillas, Stroke Fellow at University of Montreal Hospital Center, shared on LinkedIn:
”DAY 1: TRACE-5: Tenecteplase improved 90-day functional outcomes and early reperfusion compared with low-dose alteplase, with no safety difference — interim phase II results.”
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
May 20, 2026, 06:09Jesse Solar: Supporting Safer Pregnancies Through Clot Awareness
-
May 20, 2026, 05:59Enhancing Patient Care Through Hemophilia Education – Kenya Haemophilia Association
-
May 20, 2026, 05:42Muhammad Bilal: Why Reticulocyte Counts Matter in Anemia Evaluation
-
May 20, 2026, 04:06RishiRaj Sinha: Improving Blood Safety Systems in Resource-Limited Settings
-
May 19, 2026, 20:00Christoph B. Olivier: CYP2C19 Genotype, Platelet Reactivity and Risk Stratification in AF Patients Undergoing PCI
-
May 19, 2026, 16:41Selina Marwa: Strengthening Sickle Cell Disease Prevention and Care in Africa
-
May 19, 2026, 16:34Congratulations to the NNHF Project of the Year 2026 Winner
-
May 19, 2026, 16:32Veronica Sanchez: Early Screening Matters in CKM Syndrome
-
May 19, 2026, 16:24Fredrick Chalinga: The Science Behind Recombinant Factor VIIa in Hemophilia A